CAESAREA, Israel, April 10, 2019 /PRNewswire/ -- Global digital therapeutics innovator, DarioHealth Corp. (NASDAQ: DRIO), today announced the launch of a new version of its acclaimed Dario® system and DarioEngage™ platform.
The enhancements in the updated platform target three key areas: (1) driving user engagement through digital intuitive experience and tools, (2) lowering barriers to behavioral change for people with chronic conditions and (3) streamlining experience and process efficiency for both individual users and their coach.
The Company's first goal is driving ever stronger user engagement by implementing a more intuitive and personalized experience in the individual user application as well as in the coaching platform. Enhanced personalization to each person's particular needs and personality is elaborated through robust, sophisticated Customer Engagement Management (CEM) functions and processes.
This in turn, allows for lowering psychological barriers to change. For example, the best digital channels and processes are selected to motivate each user according to their preferences and to elicit the most effective responses. Digitizing our onboarding process contributes to this customization while it improves scalability to a much larger number of users being onboarded. Our onboarding, navigation and support team can now focus on exceptions and persons who need more assistance.
The system improves user personalization to orient its users to the most relevant set of topics that they should be aware of or work on. Communication is ever more engaging and adapted per user, per channel and per campaign.
Practically, many functions are new or redesigned: graphic intuitive tools, contextual progress alerts, additional educational content, interactive troubleshooting, enhanced in-app reports that increase visibility on personal results. Finally, we revised the algorithm for rating and review on the Apple Store (iOS) and on Google Play (Android) to receive authentic user feedback at the most meaningful moments for them.
"With these latest improvements, Dario pushes the boundaries of the user experience for both the patient and her provider, allowing for additional content, more engagement and a more meaningful dialogue," commented Erez Raphael, DarioHealth's CEO. "Dario demonstrates its commitment as a leading Digital Therapeutics solution to achieve the best outcomes and everyday quality of life in a personalized way and in a sustainable manner."
About DarioHealth Corp.
DarioHealth Corp. (Nasdaq: DRIO) is a leading global Digital Therapeutics (DTx) company revolutionizing the way people manage their health across the chronic condition spectrum. By delivering evidence-based interventions that are driven by data, high-quality software and coaching, we developed a novel approach that empowers individuals to adjust their lifestyle in a personalized way. Our Cross Functional Team operates at the intersection of life sciences, behavioral science and software technology to deliver highly engaging therapeutic interventions. Already one of the highest rated diabetes solutions, its user-centric approach is loved by tens of thousands of consumers around the globe. DarioHealth is rapidly moving into new chronic conditions and geographic markets.
Cautionary Note Regarding Forward-Looking Statements
This news release and the statements of representatives and partners of DarioHealth Corp. (the "Company") related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate," or "continue" are intended to identify forward-looking statements. For example, when the Company discusses the specific updates to its platform, when the Company states that the latest platform developments results in additional content, more engagement and a more meaningful dialogue, that the Company demonstrates its commitment as a leading Digital Therapeutics solution to achieve the best outcomes and everyday quality of life in a personalized way and in a sustainable manner and that the Company is rapidly moving into new chronic conditions and geographic markets,, it is using forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company's commercial and regulatory plans for Dario) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
SOURCE DarioHealth Corp.